Good News! Advanced Cell Technology Inc. announced treatment of a second patient with dry age-related macular degeneration (AMD). In a press release, Gary Rabin, chairman and CEO of the company said that the patient is recovering well: “So far, there have not been any complications or side effects due to the stem cell-derived RPE cells, and we will continue monitoring the patients for safety, tolerability and efficacy of this therapy,”
The clinical trials are designed to determine the safety and effects of sub-retinal implantation of retinal pigment epithelial (RPE) cells derived from human embroynic stem cells. ACT trials are one of the four ongoing clinical trials for the treatment of age-related macular dystrophy and Stargardt's macular dystrophy.
Earlier in January, ACT announced safe stem cell transplantation treatment of first patients. Currently, the company is conducting three trials in United States and Europe. Each trial will have 12 people, who will be monitored for safety and tolerability of hESC-derived RPE cells at 12 months.
The clinical trials are designed to determine the safety and effects of sub-retinal implantation of retinal pigment epithelial (RPE) cells derived from human embroynic stem cells. ACT trials are one of the four ongoing clinical trials for the treatment of age-related macular dystrophy and Stargardt's macular dystrophy.
Earlier in January, ACT announced safe stem cell transplantation treatment of first patients. Currently, the company is conducting three trials in United States and Europe. Each trial will have 12 people, who will be monitored for safety and tolerability of hESC-derived RPE cells at 12 months.
No comments:
Post a Comment